roxy_nash said:

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my…

Genuinely useful, thank you. I had the facts and not the framework. Taking it to my next appointment.

Clinical perspective, offered as context rather than as advice.

6 month update on cardiovascular risk: down 49 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

newstart_MO said:

Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 →…

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].

This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.

wei_SG said:

SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 4 of 5 diagnostic criteria to meeting ZERO after 9 months of treatment.

The 5 criteria (and my journey):

1. Waist circumference: 48" → 34" ✅ Resolved
2. Triglycerides: 256 → 96 ✅ Resolved
3. HDL: 32 → 58 ✅ Resolved
4. Blood pressure: 146/90 → 119/73 ✅ Resolved
5. Fasting glucose: 121 → 84 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part.